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Phosphoinositide 3-kinases (PI3Ks) regulate several cellular functions that are critical for
cancer progression and development, including cell survival, proliferation and migration.
Three classes of PI3Ks exist with the class I PI3K encompassing four isoforms of the
catalytic subunit known as p110α, p110β, p110γ, and p110δ. Although for many years
attention has been mainly focused on p110α recent evidence supports the conclusion
that p110β, p110γ, and p110δ can also have a role in cancer. Amongst these, accumulating
evidence now indicates that p110γ is involved in several cellular processes associated with
cancer and indeed this specific isoform has emerged as a novel important player in cancer
progression. Studies from our laboratory have identified a specific overexpression of p110γ
in human pancreatic ductal adenocarcinoma (PDAC) and in hepatocellular carcinoma (HCC)
tissues compared to their normal counterparts. Our data have further established that
selective inhibition of p110γ is able to block PDAC and HCC cell proliferation, strongly
suggesting that pharmacological inhibition of this enzyme can directly affect growth of
these tumors. Furthermore, increasing evidence suggests that p110γ plays also a key role
in the interactions between cancer cells and tumor microenvironment and in particular
in tumor-associated immune response. It has also been reported that p110γ can regulate
invasion of myeloid cells into tumors and tumor angiogenesis. Finally p110γ has also been
directly involved in regulation of cancer cell migration. Taken together these data indicate
that p110γ plays multiple roles in regulation of several processes that are critical for tumor
progression and metastasis. This review will discuss the role of p110γ in gastrointestinal
tumor development and progression and how targeting this enzyme might represent a
way to target very aggressive tumors such as pancreatic and liver cancer on multiple
fronts.
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INTRODUCTION
Gastrointestinal cancers comprise a group of cancers that affect
the gastrointestinal tract and include esophageal, stomach, liver,
pancreatic and colorectal cancer. Gastrointestinal cancers have
one of the poorest prognoses among all cancers partly because of
their silent nature and tendency for late discovery but also because
of their peculiar resistance to chemotherapy and radiation ther-
apy (Lockhart et al., 2005; Schneider et al., 2005; Thrumurthy
et al., 2013; Zhang, 2013; Brenner et al., 2014; Singh et al., 2014).
The prospect for patients with liver and pancreatic cancer is
particularly dismal. For instance, the 5 year survival rate for pan-
creatic ductal adenocarcinomas (PDAC) is the lowest among all
cancers (Li et al., 2004). Similarly in 2011 hepatocellular carci-
noma (HCC) was estimated as the second and sixth leading cause
of cancer-related death in men and women respectively (Jemal
et al., 2011). There have been great advances in survival rates for
many types of cancers over the past few decades but hardly any
Abbreviations: EC, endothelial cells; GPCR, G-protein coupled receptor; HCC,
hepatocellular carcinoma; LPA, lysophosphatidic acid; mTOR, mechanistic target
of rapamycin; PDAC, pancreatic cancer adenocarcinoma; PI3K, phosphoinositide
3-kinase; RTK, receptor tyrosine kinase; S1P, sphingosine-1-phosphate.
change for PDAC and HCC. There are very few treatments for
PDAC, most of them just palliative. Similarly only a small per-
centage of patients with HCC are eligible for surgery since the
majority of patients present with advanced or unresectable disease
(Kuper et al., 2000; Thomas et al., 2010; Singh et al., 2014). For
many years systemic chemotherapy also proved to be only mini-
mally effective (Ryder, 2003; Thomas et al., 2008) and currently
only the multikinase inhibitor sorafenib is approved for advanced
HCC patients (Thomas et al., 2010). There is therefore an urgent
need to better understand the mechanisms underlying progres-
sion of these cancer types in order to develop novel potential
chemotherapeutic agents.
It is well known that mutations in K-Ras oncogene occur in
75–90% of PDAC and accumulate early in the disease progres-
sion (Moskaluk et al., 1997; Hruban et al., 2000). On the other
hand, metastatic colorectal cancer represents one of the largest
hurdles in cancer treatment and metastatic colorectal tumors
with a mutation in K-Ras do not respond to available treat-
ments such as anti-epidermal growth factor receptor monoclonal
antibodies (Brand andWheeler, 2012). K-Ras signaling promotes
the neoplastic phenotype via activation of downstream targets
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that control membrane trafficking, cellular proliferation, differ-
entiation and cytoskeleton organization (Lockhart et al., 2005).
A key downstream target of the Ras family is phosphoinosi-
tide 3-kinase (PI3K), the enzyme responsible for generation of
3-phosphorylated phosphoinositides and activation of the pro-
tein kinase B/Akt (Kodaki et al., 1994; Chang et al., 1997; Khwaja
et al., 1997; Luo et al., 2003). Indeed activation of Akt has
been observed in PDAC and represents a biological indicator of
the aggressiveness of the disease (Yamamoto et al., 2004). Akt
and in particular its downstream effector mechanistic target of
rapamycin (mTOR) have also been established as key molecu-
lar targets in HCC and inhibitors of these molecules have been
tested in clinical trials (Shen et al., 2013). Although eight dis-
tinct PI3K isoforms exist most of the studies on PI3K and cancer
have been focused so far on one specific isoform, p110α that has
been found to be mutated in several cancer types. Only recently
increasing evidence has suggested that other PI3K isoforms may
also play a non-redundant role in different tumor settings. The
aim of this review is to summarize the evidence indicating that the
PI3K isoform p110γ plays a key role in gastrointestinal cancers.
PHOSPHOINOSITIDE 3-KINASES
PI3Ks catalyze the phosphorylation of lipids known as phos-
phoinositides in position 3 of their inositol rings (Falasca
and Maffucci, 2012). Phosphatidylinositol 3,4,5-trisphosphate
[PtdIns(3,4,5)P3], originally identified in activated neutrophils
from human donors (Traynor-Kaplan et al., 1988), is the best
characterized of the PI3K lipid products and it plays a key role
in activation of several signaling molecules. These include Akt, 3
phosphoinositide dependent protein kinase 1 and their effector
proteins such as mTOR that in turn regulate signaling cascades
involved in cell growth, survival, proliferation, motility and mor-
phology. It is now well-established that the PI3K/Akt pathway
plays a pivotal role in several processes that are critical for cancer
development and progression including inhibition of apoptosis,
stimulation of cell proliferation and drug resistance (Luo et al.,
2003; Takeda et al., 2004). Indeed it has been estimated that at
least 50% of all cancer types present some deregulation of this
signaling pathway (Yuan and Cantley, 2008). In particular, the
PI3K/Akt pathway is activated in almost 60% of PDAC (Bondar
et al., 2002; Schlieman et al., 2003) and it plays a critical role in
HCC (Zhou et al., 2011).
Eight PI3K isoforms exist in mammalian cells and they have
been grouped into three classes according to their structure and
substrate specificity (Vanhaesebroeck et al., 2001; Falasca and
Maffucci, 2007, 2012) with the PI3K class I encompassing four
isoforms of the catalytic subunit known as p110α, p110β, p110γ,
and p110δ. Amongst these, p110α has a well-established role
in cancer and gain of function of this isoform due to muta-
tion of its gene PIK3CA is common in several human cancers
(Samuels et al., 2004; Zhao and Vogt, 2008). Whilst mutations
to PI3K are commonly associated with PIK3CA it is important
to notice that mutations have actually been found in all PI3K
isoforms, although their prevalence and functional relevance in
disease is considered limited. An overview of these mutations
can be found on the COSMIC website (http://www.sanger.ac.uk/
genetics/CGP/cosmic/). Although somatic mutations of the genes
encoding the other isoforms are less frequent, accumulating data
now suggest that p110β, p110γ, and p110δ can also have a role in
cancer.
It was previously reported that while overexpression of wild-
type p110α does not have transforming potential, overexpression
of the wild-type catalytic subunits p110β, p110γ, and p110δ is suf-
ficient to induce an oncogenic phenotype in cultured cells (Kang
et al., 2006). These data suggested that increased expression lev-
els of the “non α” catalytic subunits rather than gain of function
mutations can be relevant in cancer development and progres-
sion. Indeed increased levels of both p110β and p110δ have
been observed in glioblastoma and in some colon and bladder
tumors (Bénistant et al., 2000; Knobbe and Reifenberger, 2003).
p110β has been shown to stimulate cell proliferation and inva-
sive cell growth (Czauderna et al., 2003) whereas p110δ controls
proliferation in acute myeloid leukemia (Sujobert et al., 2005)
and migration of breast cancer cells (Sawyer et al., 2003). More
recently it has been reported that inactivation of p110δ in mice
models inhibits different cancer types and induces tumor regres-
sion (Ali et al., 2014). Interestingly, amongst the distinct cancer
models investigated in this study, the authors also reported that
treatment with PI-3065, a small molecule inhibitor with selec-
tivity for p110δ, prolonged survival and reduced the incidence
of macroscopic metastases in the LSL KRasG12D/+; p53R172H/+;
PdxCretg/+ model of PDAC (Ali et al., 2014).
Accumulating evidence from several groups indicates that the
class IB isoform p110γ has a role in several cellular processes
involved in tumor development and progression, including pro-
liferation of pancreatic and liver cancer cells (Edling et al., 2010;
Dituri et al., 2012), tumor angiogenesis (Hamada et al., 2005),
drug resistance in chronic myeloid leukemia cells (Hickey and
Cotter, 2006) and many more processes. This review will discuss
the current evidence supporting the conclusion that inhibition of
p110γ can represent an important strategy to target cancers on
multiple fronts.
p110γ
The PI3K catalytic subunit p110γ is encoded by the PIK3CG gene,
located on chromosome 7q22.3 and its activity is modulated via
interaction with the p101 (PIK3R5) and p87 (PIK3R6) regulatory
subunits (Fyffe et al., 2013). The original classification of this iso-
form into the class IB subgroup of PI3Ks mainly derived from the
observation that p110γ can be activated downstream of G-protein
coupled receptors (GPCRs). Evidence however suggests that tyro-
sine kinase receptors (RTKs) can also activate p110γ (Ptasznik
et al., 1996; Vanhaesebroeck et al., 2010). Importantly, Ras has
also a key role in p110γ activation.
p110γ is mainly expressed in hematopoietic cells and is
involved in immune, inflammatory and allergic responses
(Vanhaesebroeck et al., 2010). Several studies have indicated a
key role for this isoform in migration of hematopoietic cell types.
For instance it has been reported that p110γmodulates leukocyte
chemotaxis to inflammatory sites and in response to chemoat-
tractant agents and it is also involved in motility of dendritic cells
(Del Prete et al., 2004). Both p110γ and p110δ are involved in
natural killer cell development and migration toward the sites of
inflammation and in T-lymphocyte migration and development
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(So and Fruman, 2012). In addition to a specific role inmigration,
p110γ can also regulate T-lymphocyte proliferation and cytokine
production (So and Fruman, 2012). It has also been demonstrated
that combined inactivation of p110γ and p110δ impairs B cell
development and reduces B cell numbers to a greater extent than
p110δ inactivation alone (Beer-Hammer et al., 2010). The lipid
kinase activity of the enzyme seems to be important for regu-
lation of these processes and indeed p110γ could play a role in
leukocyte polarization and migration by regulating the spatial
accumulation of PtdIns(3,4,5)P3, the organization of F-actin for-
mation and integrin-based adhesion at the leading edge (Hirsch
et al., 2000). Interestingly it has been demonstrated that p110γ
also possesses a serine/threonine protein kinase activity that is
independent from its lipid kinase activity (Hirsch et al., 2001).
Specifically it has been reported that p110γ plays a key role in
platelet aggregation and thrombosis by regulating αIIb/β3 inte-
grin adhesive function in platelets downstream of P2Y12 through
a mechanism that is independent from its lipid kinase activity
(Hirsch et al., 2001). In addition it has been reported that p110γ
can control cardiac contractility through formation of a multi-
protein complex with PDE3B and independently from its kinase
activity (Patrucco et al., 2004). Taken together these data indicate
that p110γ can be involved in several cellular functions through
distinct molecular mechanisms.
ROLE OF p110γ IN CANCER CELL PROLIFERATION
Although p110γ is primarily expressed in leukocytes and has a
well characterized role in immunity (Hirsch et al., 2014) evi-
dence also indicates a role for this PI3K isoform in some cancer
types. It must be noted that an original investigation reported
that p110γ−/− mice on 129J background developed macroscop-
ically visible tumors mainly at the proximal and distal parts of
the large intestine (Sasaki et al., 2000). However, the authors did
not observe the same tumor phenotype after backcrossing these
mice onto a C57BL/6 background, neither they observed forma-
tion of tumors when they retargeted the allele in different ES
cells using the same targeting construct. Therefore, the authors
changed their original conclusion that inactivation of p110γ leads
to development of invasive colorectal adenocarcinomas in mice
(Sasaki et al., 2000) by stating that this inactivation does not in
itself cause colon cancer (corrigenda Sasaki et al., 2003).
Although the prevalence and functional relevance of muta-
tions in PI3Ks other than p110α are considered limited it is
worth mentioning that significant recurrent mutations have been
seen in both PIK3CG (9.7%) and PIK3C2B (12.9%), the gene
encoding for the class II isoform PI3K-C2β, in lung cancer (Liu
et al., 2012). Interestingly PIK3CG is located in a region of
chromosome band 7q22 that is frequently deleted in myeloid
malignancies.
Recently, new driver mutations in pancreatic cancer have been
identified using cancer-specific high-throughput annotation of
somatic mutations (Carter et al., 2010). Importantly, PIK3CG
contains the second highest scoring predicted driver mutation
among the set of genes not previously identified as a driver in pan-
creatic cancer. The specific PIK3CGmutation identified is R839C
and the residue Arg 839 is located within the C-terminal catalytic
domain. Although the authors suggest that this mutation may
lead to a loss of function of the enzyme based on X-ray crystal
structure (Carter et al., 2010) it actually remains to be established
whether it indeed results in modulation of p110γ catalytic activity
and the potential functional consequences on pancreatic cancer
cells.
Recent studies in our laboratory have identified a selective
accumulation of p110γ in specific cancer types. In particu-
lar, in an extensive investigation of the expression of all PI3Ks
we detected a specific overexpression of p110γ in PDAC tis-
sues compared to normal counterparts (Edling et al., 2010).
Similarly immunohistochemistry analysis of PI3Ks in HCC and
paired peritumoral human tissues showed p110γ expression
in HCC tissues, in particular in epithelial cancer cells (Dituri
et al., 2012). Importantly p110γ correlated with the prolifer-
ative marker Ki-67 in these tissues, indicating accumulation
of this isoform in cancer cells with high proliferative index
(Dituri et al., 2012). Consistent with this, our data demon-
strated that p110γ is required for PDAC and HCC cell prolifer-
ation. Specifically we reported that chemical inhibition as well
as selective siRNA-mediated downregulation of p110γ reduced
pancreatic cancer cell growth without increasing cell apoptosis
(Edling et al., 2010). Similarly we showed that downregula-
tion of p110γ in HCC cell lines specifically induced arrest of
cell cycle in the G2/M phase through modulation of p21 levels
(Dituri et al., 2012). These data indicate that p110γ has a spe-
cific role in regulation of cancer cell proliferation and strongly
suggest that overexpression of p110γ has a functional role in
progression of PDAC and HCC. The molecular mechanisms reg-
ulating p110γ overexpression in specific cancer types are yet to be
established.
Taken together these data suggest that inhibition of p110γ
can inhibit proliferation of specific cancer types. In this respect
we recently demonstrated that treatment with the caffeine ana-
log CGS 15943 inhibited proliferation of HCC and PDAC cell
lines (Edling et al., 2014). Interestingly, a kinase profiler analy-
sis revealed that CGS 15943 is able to inhibit p110γ (Edling et al.,
2014), further supporting the conclusion that targeting this PI3K
isoform may prove beneficial to directly reduce PDAC and HCC
growth (Falasca et al., 2011).
ROLE OF p110γ IN CANCER METASTASIS
Metastasis, the ability of cancer cells to spread from a primary
site and form tumors at distant sites, is the main cause of death
of most cancer patients. Several steps regulate the development
of metastasis including migration of cancer cells out of the pri-
mary tumor, local invasion, intravasation into the circulatory
system, survival, extravasation, initiation and maintenance of
micro-metastases at distant sites and vascularization of the result-
ing tumors (Nguyen and Massague, 2007). A peculiar feature of
this process is the variability in metastatic tissue tropism shown
by different types of cancer. Indeed, even though cancer cells can
spread to almost every area of the body, each cancer type shows
specific preference for common regions where cancer may spread
to (Nguyen et al., 2009). Cancer cells with high metastatic poten-
tial are characterized by high proliferation and migration. The
endogenous signaling pathways associated with high metastatic
potential remain unclear.
www.frontiersin.org October 2014 | Volume 5 | Article 391 | 3
Falasca and Maffucci p110gamma in gastrointestinal cancers
Although it was well established that p110γ is involved in
the regulation of migration of different cell types, including
leukocytes and endothelial cells (ECs) (as discussed below) only
recently a specific role for this isoform in regulation of cancer cell
dissemination and metastasis has been suggested (Attoub et al.,
2008; Brazzatti et al., 2012; Xie et al., 2013). Specifically it has
been reported that shRNA-mediated downregulation of p110γ
reduces the ability of breast cancer cells MDA-MB-231 to metas-
tasize in vivo (Brazzatti et al., 2012). Similar data were obtained
in the 4T1.2 mouse model of breast cancer (Brazzatti et al., 2012).
Several mechanisms of p110γ-dependent regulation of metastasis
formation have been proposed. For instance recent data indicate
that p110γ exerts transforming functions via several mechanisms
in human colon epithelial cancer cells, including alteration of
homotypic cell–cell adhesion and induction of collagen type I
invasion through canonical pro-invasive pathways (Attoub et al.,
2008). The pro-metastatic activity of p110γ in metastatic epithe-
lial carcinoma cells seems to involve its ability to prevent anoikis,
an apoptotic process resulting from disruption of cell-matrix
interaction-dependent survival (Brazzatti et al., 2012). Evidence
also suggests that p110γ can be directly involved in cancer cell
migration and invasion, as it has been shown in MDA-MB-231
(Brazzatti et al., 2012; Xie et al., 2013) and in melanoma cells
(Monterrubio et al., 2009) in response to the chemokine CXCL12.
In addition, p110γ is involved in lysophosphatidic acid (LPA) sig-
naling (Edling et al., 2010). LPA signaling has been shown to
play a role in cancer and in particular in cancer cell migration
(Van Meeteren and Moolenaar, 2007). Both CXCL12 and LPA are
key regulators of metastatic processes in several cancers including
gastrointestinal cancers. Interestingly CXC chemokine receptor 4
plays an important role in pancreatic cancer metastasis, and ini-
tiates G-protein signaling when activated by its ligand CXCL12
(Marchesi et al., 2004).
Taken together these data support the conclusion that inhi-
bition of p110γ can affect cancer cell migration and metastasis
formation.
ROLES OF p110γ IN ANGIOGENESIS
A prerequisite for tumor growth is the supply of nutrients and
oxygen that are provided by the formation of new blood vessels in
a process named tumor angiogenesis (Welti et al., 2013). Several
cancer types, including HCC, strongly rely on tumor angiogenesis
and anti-angiogenic strategies are either in use or are currently
being tested in clinical trials as anti-cancer strategies in several
tumor settings.
Tumor angiogenesis involves the coordinated action of dif-
ferent cell types that are normally present or are recruited to
the tumor site. In particular tumor angiogenesis is the results
of proliferation, migration and remodeling of activated ECs that
eventually form novel capillaries (Welti et al., 2013). Several trans-
genic mouse models have established the pivotal role for class
I PI3K isoforms in EC functions. Specifically a central role for
p110α has been demonstrated by the observation that knock-
out mice for this isoform die during embryogenesis (E9.5) due
to defects in vasculogenesis and this was confirmed by knock-in
strategies (Graupera et al., 2008). Transgenic mouse models fur-
ther indicated specific roles for p110γ in ECs. Indeed, although
knock out and knock in p110γ mice were mainly characterized
by immunological and cardiac (in the case of p110γ−/− mice)
defects (Morello et al., 2009) it was also observed that mus-
cles from p110γ−/− mice presented reduced capillarization and
arteriogenesis following unilateral limb ischemia compared to
wild type mice which in turn resulted in delayed blood flow
recovery (Madeddu et al., 2008). A role in proliferation and sur-
vival of ECs was suggested by the observation that the number
of BrdU-positive capillaries was reduced in p110γ−/− ischemic
gastrocnemius muscles compared to wild type whereas the per-
centage of apoptotic capillaries was increased. Interestingly, evi-
dence also suggested that the lipid kinase activity of p110γ was
not required in regulation of these cellular processes since post-
ischemic neovascularization was not impaired and microvascular
apoptosis was not increased in p110γKD/KD (kinase dead) mice.
Furthermore, a defect in proliferation, survival and migration
induced by stromal cell-derived factor-1 was detected in endothe-
lial progenitor cells from p110γ−/− but not from p110γKD/KD
mice, suggesting that p110γ may regulate endothelial progeni-
tor cells function and muscular angiogenesis through a mecha-
nism independent of its kinase activity. On the other hand both
p110γ−/− and p110γKD/KD endothelial progenitor cells showed
reduced integration into endothelial networks, indicating that
the lipid kinase activity is required for some steps of capillary
formation.
Evidence from several groups, including our own, has also
identified a role for p110γ in regulation of EC migration.
Specifically a previous study demonstrated that both p110β and
p110γ are involved in sphingosine 1-phosphate (S1P)-mediated
EC migration (Heller et al., 2008). We further reported that
chemical inhibition and siRNA-mediated downregulation of
p110γ reduced S1P-induced as well as high density lipopro-
tein 3-induced EC migration (Tibolla et al., 2013). Importantly
downregulation of p110γ also inhibited S1P- and high density
lipoprotein 3-induced remodeling of ECs onMatrigel indicating a
key role for this isoform in regulation of capillary tube formation
(Tibolla et al., 2013). Interestingly, analysis of cell motility further
indicated a specific role for p110γ in regulation of cell speed and
provided direct evidence that different PI3Ks are involved in EC
tubule formation.
These data support the conclusion that inhibition of p110γ can
reduce EC remodeling and formation of novel capillaries network
and can therefore possibly represent a novel strategy to counteract
tumor angiogenesis.
ROLES OF p110γ IN STROMA CELLS
Through generation of lipid second messengers and activation of
several signaling molecules PI3Ks regulate several cellular func-
tions, such as cell growth, survival, cytoskeletal remodeling and
trafficking of intracellular organelles in many different cell types.
The generation of transgenic mice has further revealed a critical
role for some isoforms in regulation of the immune system in vivo
in particular p110δ and p110γ that are preferentially expressed in
immune cells.
It is now well-established that the immune system plays
an important role during tumorigenesis (Sun and Karin,
2014). Deregulated cell proliferation and survival, genome
Frontiers in Physiology | Gastrointestinal Sciences October 2014 | Volume 5 | Article 391 | 4
Falasca and Maffucci p110gamma in gastrointestinal cancers
destabilization and induction of migration and invasion (Elinav
et al., 2013) as well as different steps involved in metastasis
development (Antonioli et al., 2013) have all been associated
with inflammation. For instance invasion and intravasation of
cancer cells into blood and lymphatics vessels can be regu-
lated by tumor-associatedmacrophages and inflammatory factors
that can increase vascular permeability, prostaglandin produc-
tion and matrix metalloproteinases-mediated tissue remodeling
(Quail and Joyce, 2013).
Infiltrative macrophages and inflammatory cells have been
detected in PDAC stroma which has been intensely investigated
in recent years. Indeed PDAC is characterized by desmoplasia
deriving from pancreatic stellate cells that proliferate and pro-
duce a dense extracellular matrix consisting of collagen, laminin
and fibronectin (Apte et al., 2013). Although several lines of
evidence support the conclusion that interaction between pan-
creatic stellate cells and PDAC cells plays a critical role in
the disease (Haqq et al., 2014) this information has not been
translated into efficient therapeutic strategies yet. In fact while
preclinical studies indicated potential benefit in targeting the
stroma-associated Hedgehog signaling pathway corresponding
clinical trials yielded disappointing results. A renewed interest
in understanding the cause of this failure has recently revealed
a protective role for the stroma against PDAC (Lee et al., 2014;
Özdemir et al., 2014; Rhim et al., 2014) indicating that alterna-
tive strategies must be investigated (Gore and Korc, 2014). HCC
progression is also frequently associated with continuous hepa-
tocyte death and inflammatory cell infiltration (He and Karin,
2011).
Several lines of evidence suggest that p110γ plays a cen-
tral role in cancer-associated inflammation. For instance, in a
murine model of ulcerative colitis, it has been shown that p110γ
regulates the innate immune system by controlling colon inflam-
mation and tumor formation (Gonzalez-Garcia et al., 2010). In
this model, p110γ-deficient mice and control mice were treated
with dextran sulfate sodium to induce chronic colitis and colitis-
associated cancer. The results showed that p110γ-deficient mice
had a lower incidence of colitis-associated tumors as well as
reduced tumor multiplicity. The reduced tumor development was
a consequence of defective infiltration and activation of myeloid
cells and defective recruitment of T cells to the colon and less
colon inflammation.
It has been recently reported that a range of chemoattrac-
tants able to activate GPCRs, RTKs and Toll-like/IL-1 recep-
tors unexpectedly initiate tumor inflammation by activating
p110γ in Gr1+CD11b+ myeloid cells (Schmid et al., 2011).
While GPCRs activate p110γ in a Ras/p101 dependent man-
ner, RTKs and Toll-like/IL-1 receptors directly activate p110γ
in a Ras/p87-dependent manner. Once activated, p110γ pro-
motes inside-out activation of a single integrin, α4β1, caus-
ing myeloid cell invasion in different tumor types including
pancreatic cancer (Schmid et al., 2011). Pharmacological or
genetic blockade of p110γ suppressed inflammation, growth
and metastasis of implanted and spontaneous tumors, indi-
cating that targeting p110γ can further affect tumor pro-
gression through its effect on stroma cells and reduction of
inflammation.
ROLES OF p110γ IN CANCER METABOLISM
To meet their increasing demand of building block molecules,
cancer cells switch to a heavily glucose-dependent metabolism
(Ward and Thompson, 2012). Alteration of metabolic pathways
is very common in cancer cells and indeed reprogramming of
metabolism has been recently recognized as an emerging hall-
mark of cancer (Hanahan and Weinberg, 2011). In addition
to altered glucose metabolism it is becoming increasingly evi-
dent that alteration of lipid metabolism plays also a critical
role in cancer development. On the other hand, altered cell
metabolism, as observed during obesity and insulin resistant
conditions, is becoming increasingly associated with cancer devel-
opment and progression. Indeed, accumulating evidence now
suggests that obesity is associated with increased frequency of sev-
eral cancer types, including prostate, kidney, esophagus, breast,
endometrium cancers, as well as cancers of the stomach, colon,
pancreas, gallbladder and liver (Møller et al., 1994; Wolk et al.,
2001; Calle et al., 2003; Renehan et al., 2008; Basen-Engquist
and Chang, 2011). For instance a recent analysis, with a follow
up of 239,597 participants and 897 pancreatic cancer deaths, has
indicated that obesity is independently associated with increased
pancreatic cancer mortality in African Americans (Bethea et al.,
2014). These results are consistent with a recent study of two
large prospective cohorts comprising 902 patients with pancre-
atic cancer that also reported statistically significantly reduced
survival in patients with higher body mass index before diagno-
sis (Yuan et al., 2013). Similarly several studies have indicated a
link between obesity and increasing incidence of HCC (Møller
et al., 1994; Wolk et al., 2001; Borena et al., 2012; Schlesinger
et al., 2013; Turati et al., 2013; Karagozian et al., 2014). For
instance a prospective cohort of the Cancer Prevention Study
with more than 900,000 North American subjects revealed that
men with body mass index ≥35 kg/m2 had a higher risk of dying
from liver cancer (Calle et al., 2003). A similar study involving
362,552 Swedish men also indicated an increased risk of HCC
in individuals with body mass index ≥30 kg/m2 (Samanic et al.,
2006). The mechanisms responsible for this obesity-associated
increase in cancer incidence are not completely known. Obesity
is associated with a chronic low-grade inflammation, and spe-
cific anti-inflammatory interventions may be beneficial for the
treatment of type 2 diabetes and other obesity-related diseases.
On the other hand obesity is usually associated with insulin
resistance and with increased levels of circulating insulin that
can in turn promote cell proliferation and survival. Whether
obesity per se or the associated insulin resistance is ultimately
responsible for this increased cancer risk is still a matter of
debate.
Consistent with its central role in leukocyte chemotaxis, mast
cell degranulation, and EC activation, p110γ has been demon-
strated to be critical for obesity-induced inflammation and
insulin resistance. It has been shown that mice lacking functional
p110γ were protected from insulin resistance, metabolic inflam-
mation, and fatty liver largely because of their leaner phenotype
(Becattini et al., 2011; Kobayashi et al., 2011). This phenotype
appeared to be a consequence of decreased fat gain as a result
of increased energy expenditure despite normal caloric intake.
Indeed p110γ action on diet-induced obesity depends on p110γ
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activity within a non-hematopoietic compartment, where it pro-
motes energetic efficiency for fat mass gain. Importantly, the
metabolic modulation by p110γ depends on its lipid kinase
activity but it might also involve kinase-independent signaling.
Apart from its role in control of weight gain, data also indicate
that p110γ is directly involved in development of obesity-induced
insulin resistance. By using murine models of both diet-induced
and genetically induced obesity the role of p110γ in the accu-
mulation of tissue macrophages and the development of obesity-
induced insulin resistance was examined (Kobayashi et al., 2011).
Mice lacking p110γ exhibited improved systemic insulin sensitiv-
ity with enhanced insulin signaling in the tissues of obese animals
(Kobayashi et al., 2011). In adipose tissues and livers of obese
p110γ−/− mice, the numbers of infiltrated pro-inflammatory
macrophages were markedly reduced, leading to suppression
of inflammatory reactions in these tissues. Furthermore, bone
marrow-specific deletion and pharmacological blockade of p110γ
also ameliorated obesity-induced macrophage infiltration and
insulin resistance. These data suggest that p110γ plays a crucial
role in the development of both obesity-induced inflammation
and systemic insulin resistance. These data indicate that target-
ing p110γ can have additional beneficial effects in the context of
obesity- and insulin resistance-associated cancers. Based on this
evidence it is also tempting to speculate that p110γ inhibitionmay
have a more generic role in modulation of cancer cell metabolism
beyond the context of obesity and insulin resistant conditions.
p110γ SPECIFIC INHIBITORS
Consistent with a key role for PI3Ks in cancer development,
several inhibitors have been shown to possess anti-cancer activ-
ity in vitro and in vivo. Although PI3Ks and related signaling
pathways have been recognized as important therapeutic targets,
development of generic PI3K inhibitors has raised some con-
cerns because of the large number of physiological functions
that this family of enzymes controls. Many inhibitors of the
PI3K pathway have been generated (Falasca, 2010, 2011) that
can target either the enzymes themselves or their downstream
effectors and these agents can be divided into four major classes:
PI3K inhibitors, dual PI3K-mTOR inhibitors, Akt inhibitors and
mTOR inhibitors.
PI3K inhibitors can be divided in pan-class I PI3K inhibitors,
which target all class I PI3Ks, such as PI-103 and BEZ235
(Raynaud et al., 2007; Maira et al., 2008) and PI3K isoform-
specific inhibitors, which specifically target a single PI3K isoform.
Since p110δ and p110γ are highly enriched in leukocytes, they
are particularly desirable targets for inhibition in the treatment
of hematologic malignancies. Indeed among the first isoform-
specific PI3K inhibitors developed, the specific p110δ inhibitor
IC87114 was used to demonstrate that p110δ could play a role
in the pathophysiology of acute myeloid leukemia (Sadhu et al.,
2003). Subsequently, TGX-221, an analog of the generic PI3K
inhibitor LY294002, and AS252424 were found to selectively
inhibit p110β and p110γ respectively (Jackson et al., 2005; Pomel
et al., 2006). In the last decade, a number of pharmaceutical com-
panies have reported a wide variety of p110γ inhibitors (Venable
et al., 2010), and several X-ray crystal structures with p110γ have
been elucidated (Zvelebil et al., 2008). As a consequence, the
FIGURE 1 | Diagram summarizing the effect of p110γ on different cell
types and ultimately on cancer-associated processes.
efficacy of p110γ inhibitors generated has been demonstrated
in different biological systems (Venable et al., 2010). However,
one of the issues emerged from these studies is the selectivity of
compounds tested. On the other hand, an increased interest has
emerged in the development of dual p110δ and p110γ inhibitors
(Randis et al., 2008). More recently a potent oral p110δ and p110γ
inhibitor (IPI-145) has been characterized (Winkler et al., 2013).
It has been demonstrated that IPI-145 exerts profound effects on
adaptive and innate immunity by inhibiting B and T cell prolif-
eration, blocking neutrophil migration, and inhibiting basophil
activation. The therapeutic value of combined p110δ and p110γ
blockade was explored, and IPI-145 showed potent activity in
collagen-induced arthritis, ovalbumin-induced asthma, and sys-
temic lupus erythematosus rodent models (Winkler et al., 2013).
These findings support the hypothesis that inhibition of immune
function can be achieved through p110δ and p110γ inhibition,
potentially leading to significant therapeutic effects in multiple
inflammatory, autoimmune, and hematologic diseases.
Preclinical studies have shown that PI3K inhibition is able
to induce apoptosis and inhibit tumor growth of pancreatic
cancer xenografts (Bondar et al., 2002). Our recent data have
demonstrated that specific pharmacological inhibition of p110γ
using selective inhibitors reduces proliferation of PDAC (Edling
et al., 2010) and HCC cell lines (Dituri et al., 2012) in vitro.
Interestingly we also reported that caffeine and its analog CGS
15943 block proliferation of HCC and PDAC cell lines by inhibit-
ing the PI3K/Akt pathway (Edling et al., 2014). More specifically,
a kinase profiling assay revealed that CGS 15943 targets p110γ
therefore this study identified this compound as a promising lead
compound to develop drugs that can specifically target this PI3K
isoform in cancer (Edling et al., 2014).
CONCLUDING REMARKS
Given the predominant expression of p110γ in hematopoi-
etic cells the interest of oncologists on this specific lipid
kinase has been mainly focused on hematological malignancies.
Nevertheless, the discovery of many solid cancers where p110γ
seems to play a key role has clearly indicated that inhibition of
this specific isoform can prove beneficial in a larger spectrum
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of cancer types. Furthermore, p110γ is a valid target in different
tumor-related processes such as metastasis, angiogenesis and can-
cer associated inflammation (Figure 1). Therefore, this evidence
underlines the potential of targeting p110γ in cancer, especially
in gastrointestinal cancers. Several p110γ–specific inhibitors are
available and they have been already used to alleviate symptoms
in inflammatory chronic diseases such as rheumatoid arthritis
and systemic lupus. Testing the effect of these inhibitors in solid
cancers will represent an important future challenge. In par-
ticular, due to the central role of p110γ in regulation of the
immune system it would be critical to assess whether such a
strategy could result in potential side effects of immunosuppres-
sion. On the other hand small inhibitors designed to block the
catalytic activity of the enzyme would not be beneficial to coun-
teract its kinase-independent functions. Therefore, novel strate-
gies should be developed to identify specific inhibitors that target
the p110γ kinase-independent activity. We propose that certain
gastrointestinal cancers represent the tumor types of election
where the use of p110γ inhibitors can be particularly beneficial.
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